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Abstract
Background: Standardization of quality of life (QOL) assessment and reporting in clinical trials is
an imperative issue. While English-speaking countries have led this movement in standardization,
there persists to be a limited amount of information from non-English-speaking including Japan. In
this study, we bibliographically analyze the reporting of randomized controlled trials (RCT)
conducted in Japan that used a QOL instrument.
Methods: A PubMed search of reports published between 1970–2003 followed by an examination
of QOL reporting and its frequency of use in RCTs published from Japan.
Results:  Percentages of QOL reporting in RCTs have increased between 1970–2003 both
worldwide (0% for 1970–1974 to 4.4% for 2000–2003) and in Japan (0% to 1.8% for the identical
periods). We found and evaluated 46 RCT reports published from Japan (32 in English, 14 in
Japanese). The most commonly studied clinical condition was cancer (26, 56.5%) and the most
common intervention was drug therapy (29, 63.0%). QOL was used as the primary endpoint in 10
studies (21.7%). Authors used established QOL instruments in 12 studies (26.1%), developed
original instruments in 8 studies (17.5%) and assessed the symptoms or performance status in 10
studies (21.7%). Authors conceptually defined QOL in only 6 studies (13.0%). Neither response
rate nor number of respondents for questionnaire surveys was specified in 16 studies (34.8%);
furthermore, 11 studies (23.9%) did not describe respondents' attributes.
Conclusions: Findings on relative frequency suggested that Japanese authors of RCT reports have
less interest in QOL instruments than other international researchers in Western Europe and
North America. Examination of RCT reports published from Japan revealed that there were several
points to be improved in reporting QOL instruments. This study highlights the need to define QOL
measures specific to clinical specialty and to examine methodology for assessing and reporting
QOL.
Background
During the past two decades, ideas of health have trans-
formed from ones that focus on illness to ones that con-
sider patient well-being and quality of life (QOL) [1,2].
Currently, QOL instruments that integrate clinical and
economic indices serve as a key to understanding
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treatment outcomes [2,3]. As Spilker defines, "'Quality of
life' in clinical medicine represents the functional effect of
an illness and its consequent therapy upon a patient as
perceived by the patient [4]." Although randomized con-
trolled trials (RCT) generally have the objective of evalu-
ating intervention effect (i.e. drug, modes of care),
significant results are not recognized unless a suitable
measure of outcome is evaluated [5-7]. Accordingly, the
use of QOL assessment as an outcome measure in RCTs
continues to gain attention.
While the CONSORT statement [8] establishes methods
of RCT reporting, this guideline does not address prob-
lems with QOL instruments, standards of cultural validity
and psychometric validity. Sanders et al. [9] studied QOL
assessment in clinical trials, indicating a high frequency of
incomplete responses and a poor quality of reporting.
Findings described a need for specified standards of QOL
assessment and reporting. In 2002, international stand-
ards for QOL assessment and reporting in clinical trials
were proposed [10]. But the fact that QOL is culturally
influenced [4] reminds us that standardization based on
information having originated from English-speaking
countries may be impetuous. Accordingly, an examina-
tion of QOL-assessment methodology in RCTs collected
from nations worldwide could provide valuable insight
into the ramifications of standardization.
A PubMed-based bibliographical search found approxi-
mately 4000 reports on clinical trials published in Japa-
nese between 1987 and 2001; this ranks second to
German-published reports in number of non-English arti-
cles [11]. When limited to RCTs, the number of articles
published between 1995 and 1999 from Japanese institu-
tions ranks top amongst Asian nations and within the top
ten internationally [12]. An understanding of how QOL is
assessed in Japanese clinical trials, particularly in RCTs,
will contribute to the ongoing international discussion.
In this literature study, we calculate the number of RCT
reports that refer to QOL and compare Japanese publica-
tion trends with international ones. We then examine all
reports published from Japan as of 1970. Based on our
findings, we point to several imperative problems con-
cerning the assessment and reporting of QOL that require
further examination.
Methods
We performed a literature search of reports published
between 1970–2003 using PubMed. We first located arti-
cles reporting RCTs by using "randomized controlled
trial" as a PubMed "publication type s [pt]" tag – this was
also used as a denominator to gain relative frequency. Sec-
ond, we identified RCTs that referred to QOL by using the
free text term "quality of life". For each year, we calculated
the proportion of reports mentioning QOL among all
RCTs.
Third, we looked for RCTs published from Japan that
referred to QOL as follows: "randomized controlled trial"
[pt] AND "Quality of life" [text] AND (Japan [address] OR
Japanese [language]). Results were not only examined by
frequency of reporting, but were also assessed by hand in
more detail. Reviews, editorials, meeting abstracts, letters
and publications without abstracts were excluded from
the latter analysis.
Items of evaluation were based on previous reports
[9,13,14] and included: (1) type of subjects' condition;
(2) type of intervention tested; (3) type of QOL measures
used and whether they were validated; (4) whether QOL
was defined conceptually; (5) reasons why QOL measure-
ment was introduced into the trial; (6) whether QOL was
categorized as the primary or secondary endpoint and
description of (7) the response rate and, lastly, (8)
respondents of QOL measurements. Two of the authors
independently evaluated all articles for eligibility and
resolved disagreements by consensus. In cases when infor-
mation on QOL-instrument validation was not men-
tioned in the article, we verified what type of validation
study was conducted by checking references.
Results
Counting the number of articles with "publication type"
and a free text term, frequency of referring to QOL was
found to increase over time worldwide – from 0 (0%)
between 1970–1974 to 1930 (4.4%) between 2000–
2003. This trend was similar among reports published
from Japan with 0 (0%) in 1970–1974 to 27 (1.8%) in
2000–2003 (Figure 1).
Prevalence of reporting on QOL in randomized controlled  trials during 1970–2003 Figure 1
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65 RCT reports referring to QOL, published from Japan
during 1970–2003, were found. We excluded 19 of these
for not being RCTs (n = 4), not having an abstract (n = 1),
not reporting on QOL (n = 12) or for being a review article
(n = 2). The remaining 46 reports (32 were written in Eng-
lish and 14 were written in Japanese) met our criteria and
were evaluated (Table 1 [see additional file 1]). Table 2
and Table 3 show the distributions of conditions and
interventions examined and the language of each article.
The most commonly studied condition was oncology (15
English reports; 11 Japanese reports; 26 in total, 56.5%),
followed by cardiovascular disease (5 English reports; 0
Japanese reports; 5 in total (10.9%)) and urologic disor-
ders (4 English reports; 2 Japanese reports; 6 in total,
13.0%), with other diseases occurring in less than 10% of
reports (Table 2). The largest number of interventions was
with drugs (18 English reports; 11 Japanese reports; 29 in
total, 63.0%) followed by modes of care (9 English
reports; 3 Japanese reports; 12 in total (26.1%)); other
interventions were studied in less than 5% of reports
(Table 3).
QOL was the primary endpoint in 10 reports (7 English
reports; 3 Japanese reports; 10 in total, 21.7%). Only one
report used a generic health-related QOL instrument.
Authors defined QOL in 15 reports (9 English reports; 6
Japanese reports; 15 in total (32.6%)) (Table 4). Of these,
authors of 9 reports (5 English reports; 4 Japanese reports;
9 in total, 19.6%) described their own definitions of QOL.
After 1999, there were no RCT reports in Japanese that had
investigators' definition of QOL.
A rising trend was recognized for reports describing why
they performed a QOL assessment (Table 5) – prior to
1993, 2/7 reports (1 English report; 1 Japanese report; 2 in
total (28.6%)); between 1994–1998, 6/14 reports (2 Eng-
lish reports; 4 Japanese reports; 6 in total (42.9%));
Table 2: Subjects studied in 46 randomized controlled trials reporting on QOL
Number of trials (%)
Subjects English Reports Japanese Reports Total
Oncology 15 (46.9) 11 (78.6) 26 (56.5)
Cardiovascular diseases 5 (15.6) 0 (0.0) 5 (10.9)
Urology 4 (12.5) 2 (14.3) 6 (13.0)
Gastrointestinal diseases 3 (9.4) 1 (7.1) 4 (8.7)
Respiratory 2 (6.3) 0 (0.0) 2 (4.3)
Dentistry 1 (3.1) 0 (0.0) 1 (2.2)
Infection 1 (3.1) 0 (0.0) 1 (2.2)
Health* 1 (3.1) 0 (0.0) 1 (2.2)
Total 32 (100.0) 14 (100.0) 46 (100.0)
* Health is defined here as the effect of captopril during exercise
Table 3: Type of intervention studied in 46 randomized controlled trials reporting on QOL
Number of trials (%)
Intervention English Reports Japanese Reports Total
Drug 18 (56.3) 11 (78.6) 29 (63.0)
Mode of care 9 (28.1) 3 (21.4) 12 (26.1)
Psychological 1 (3.1) 0 (0.0) 1 (2.2)
Immunotherapy 1 (3.1) 0 (0.0) 1 (2.2)
Hormone therapy 1 (3.1) 0 (0.0) 1 (2.2)
Radiotherapy 1 (3.1) 0 (0.0) 1 (2.2)
Rehabilitation 1 (3.1) 0 (0.0) 1 (2.2)
Total 32 (100.0) 14 (100.0) 46 (100.0)Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/31
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between 1999–2003, 11/25 reports (11 English reports; 0
Japanese reports; 11 in total (44.0%)).
Table 6 shows the methods for assessing QOL in each
respective report. Authors used established QOL instru-
ments in 12 reports (11 English reports; 1 Japanese report;
12 in total (26.1%)) and modifications of established
instruments in six reports (2 English report; 4 Japanese
report; 6 in total (13.0%)). Seven reports (5 English
reports; 2 Japanese reports; 7 in total (15.2%)) used non-
established QOL instruments but quoted references that
described their methodology. Eight reports (3 English
reports; 5 Japanese reports; 8 in total (17.5%)) developed
original instruments. Except for three QOL scales in which
each was used in two reports, a different scale was used in
all reports.
Of the remaining articles, 10 reports (9 English reports; 1
Japanese report; 10 in total (21.7%)) assessed only symp-
toms or performance status, and three reports (2 English
report; 1 Japanese report; 3 in total (6.5%)) used methods
that were unclear. 30 reports (21 English reports; 9
Japanese reports; 30 in total, 65.2%) specified response
rate or number of respondents. Lastly, 35 reports
described respondents (26 English reports; 9 Japanese
reports; 35 in total (76.1%)).
Discussion
Health status, functional status, and QOL are three con-
cepts often used interchangeably to refer to the same
domain of "health." [15] Health-related QOL continues
to be used as a measure of outcome in clinical trials [16].
In the present study, we performed a literature search
using PubMed in aims of comparing QOL assessment fre-
quencies between international and Japanese RCT reports.
Our study, however, has the following limitations. A text-
based search was unable to locate articles that do not con-
tain the term, "quality of life," in the abstract, title or as a
Medical Subject Headings (MeSH). Also, PubMed does
not hold all reports of RCTs published in Japanese [17].
Nonetheless, given that there currently exists no Japanese
database of RCT-related articles in Japanese, PubMed
serves as the best descriptive database for our study.
While the number of RCT reports referring to QOL pub-
lished from Japan drastically increased after 1982, this
does not necessarily mean that a similar shift exists in rel-
ative frequency of total RCTs. The relative frequency of
Japanese RCTs rose in parallel with a rising global trend
during the 1980s. In the following decade, however, this
trend began to diverge from the international one.
Although Japanese interest in QOL measures rose in the
1990s [18,19], doubt persisted among clinicians and
Table 4: Definition of QOL in 46 randomized controlled trials reporting on QOL
Number of trials
Before 1993 1994–1998 1999–2003
English 
Reports
Japanese 
Reports
English 
Reports
Japanese 
Reports
English 
Reports
Japanese 
Reports
Total
Investigators' definition of QOL 0 (0.0) 1 (25.0) 1 (12.5) 1 (16.7) 3 (14.3) 0 (0.0) 6 (13.0)
General definition of QOL 0 (0.0) 0 (0.0) 1 (12.5) 2 (33.3) 4 (19.0) 2 (50.0) 9 (19.6)
No definition 3 (100.0) 3 (75.0) 6 (75.0) 3 (50.0) 14 (66.7) 2 (50.0) 31 (67.4)
Total 3 (100.0) 4 (100.0) 8 (100.0) 6 (100.0) 21 (100.0) 4 (100.0) 46 (100.0)
Table 5: Description of why QOL assessment was conducted in 46 randomized controlled trials reporting on QOL
Number of trials
Before 1993 1994–1998 1999–2003
English 
Reports
Japanese 
Reports
English 
Reports
Japanese 
Reports
English 
Reports
Japanese 
Reports
Total
Description provided 1 (33.3) 1 (25.0) 2 (25.0) 4 (66.7) 11 (52.4) 0 (0.0) 19 (41.3)
No description 2 (66.7) 3 (75.0) 6 (75.0) 2 (33.3) 10 (47.6) 4 (100.0) 27 (58.7)
Total 3 (100.0) 4 (100.0) 8 (100.0) 6 (100.0) 21 (100.0) 4 (100.0) 46 (100.0)Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/31
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researchers concerning the validity of subjective measures
using interviews and questionnaires [20]. At that time,
moreover, little research had focused on the methodolo-
gies of QOL assessment. This study's findings, we surmise,
reflect this history of QOL in Japan.
Among the 46 reports examined, a total of 10 studies used
QOL as a primary endpoint. Previous systematic reviews
have criticized researchers for not using a suitable health-
related QOL instrument as an outcome measure when
studying the effect of intervention [21-25]. Nevertheless,
it is still unclear as to whether this reflects a lack an appli-
cable scale or the misuse of available scales [26].
27 of the 46 reports did not describe their reasons for
using QOL as an outcome measure. It remains unclear
whether this derives from a lack of description concerning
outcome measures or insufficient discussion on the need
for QOL assessment. It has also been suggested that spon-
sors and researchers may measure health-related QOL in
aims of raising the image of a clinical trial or of the drug
under investigation [27]. This study was unable to address
this issue because all reports lacked a description of spon-
sorship and/or conflict of interests. Further studies are
needed to investigate and delineate the respective objec-
tives and significance of QOL assessment within each
field.
Gill et al. [13] conducted a systematic review of 75 reports
published between 1987 and 1991 containing the term
QOL in the title and reported that only 15% of reports
defined QOL. Our findings show that 32.6% of reports
define QOL. Editorial procedures and limited word count,
however, may possibly be associated with why QOL
measurement selection and its definition were not men-
tioned. 60.9% of reports used neither an established QOL
instrument nor an instrument without modification. This
lack of consistency indicates the need for studies to
describe their definition of QOL – at least when using
their own instrument. Moreover, 50% of studies that used
an established instrument did not provide a definition of
QOL. This was probably due to the assumption that QOL
assessment is equivalent to an establishment scale. This
point to the need for defining QOL and for better descrip-
tion as to why an established scale was selected
In the present study, all 15 (32.6%) reports that defined
QOL were published after 1993. Furthermore, only four
of the 10 reports that used QOL as their primary endpoint
actually provided a definition. A total of nine reports
(19.6%) that measured symptoms and/or reported the
assessment of performance status (PS) in terms of QOL
did not clearly define QOL. Only one report published in
1993 used the measure of PS in defining QOL assessment.
While the percentage of reports that assessed symptoms
and PS in terms of QOL was 36% (5 out of 14 reports)
before the mid-1990s, this percentage dropped to 15.6%
(5 out of 32 reports) in later years. In light of this, we sur-
mise that, since 1997, QOL instruments that use a symp-
tom index have slowly been replaced with subjective QOL
instruments. That is, QOL instruments that measure
subjective QOL have gained acceptance and the concept
of QOL has shifted from being objective to subjective.
Clinical researchers can use QOL instruments to measure
treatment efficacy, yet questions remain as to how QOL
instruments should be selected, used, and how findings
should be interpreted [28]. We based our current review
on the methods discussed in the reports by Gill et al [13].
and the Scientific Advisory Committee of the Medical
Outcomes Trust [14]. This review also took the following
items into consideration when examining instrument
selection: whether the instrument was disease-specific or
comprehensive, whether or not established instruments
were tested for validity, whether or not modification of an
established instrument was tested for validity, whether or
not instruments were tested for validity despite the cita-
tion of references, and whether or not instruments were
original (developed by the investigators themselves).
Table 6: Type of evaluated measure used in 46 randomized controlled trials reporting on QOL
Number of trials (%)
Measure English Reports Japanese Reports Total
Established QOL instruments 11 (34.4) 1 (7.1) 12 (26.1)
Modifications of established QOL instruments 2 (6.3) 4 (28.6) 6 (13.0)
Non-established QOL instruments (references quoted) 5 (15.6) 2 (14.3) 7 (15.2)
Original QOL instrument (non-established) 3 (9.4) 5 (35.7) 8 (17.5)
Symptoms or performance status only 9 (28.1) 1 (7.1) 10 (21.7)
Unclear measure 2 (6.3) 1 (7.1) 3 (6.5)
Total 32 (100.0) 14 (100.0) 46 (100.0)Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/31
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Most of reports of this review used different disease-spe-
cific scales, and this may be due to the wide range of dis-
eases studied in such a limited sample of RCT reports.
A serious problem apparent in several studies is the use of
original instruments that have not been tested for validity
or reliability. Garratt [26] has cautioned against this "easy
development of new instruments." Previous studies have
also indicated the need to consider issues of cultural phe-
nomenon, spirituality [29] and level of medical-service
satisfaction in the context of QOL assessment. QOL, being
a multifactorial concept, should not be assessed with only
one generic instrument [28] or with only one disease-spe-
cific instrument, but rather with multiple instruments.
Sanders et al. [9] found that respondents are not clearly
described in approximately 30% of RCT reports that use
QOL. Our findings intimate the same. The reason may be
a lack of interest in the issue of respondents' criteria and/
or a mere insufficiency in reporting procedures. Slevin et
al. [30] suggests that QOL assessment may have more
validity when conducted by the patient him/herself than
when conducted by medical providers. We found 18.8%
(6 out of 32 articles) of English reports and 35.7% (5 out
of 14 articles) of Japanese reports did not describe
respondents. Moher et al. [31] further exemplifies that
RCT articles written in English provide a clearer descrip-
tion than similar reports written in a non-English lan-
guage. Our findings show that 34.4% (11 out of 32
articles) of English written reports as opposed to 35.7% (5
out of 14 articles) of Japanese-written reports showed nei-
ther response rate nor number of respondents. These
insufficiencies in description highlight a need for better
reporting standards. Needless to say, a study's quality and
validity are most easily assessed by information described
in a report [32-34].
Conclusions
Japanese interest in QOL assessment used in RCTs may
remain at low levels when compared internationally. Our
findings suggest insufficient discussion on when to use
QOL as an outcome measure, how to select an appropri-
ate scale and how to accurately use that scale. Further dis-
cussion is needed from the standpoints of study objective
and psychometrics on the use of QOL assessment as an
outcome measure in RCTs and on assessment
methodology.
Before doing so, however, it is essential to establish a clear
definition of QOL within each field for each particular
disease. Contemporary research concerning QOL assess-
ment in RCTs has demonstrated the need for international
minimal standards including, but not limited to, scale
selection, minimal standards of psychometric validity,
and agreed standards of cultural validity [10]. We are con-
fident that by collecting data from nations worldwide, a
basis for further discussion on an international frame-
work for QOL will foster. By participating in this discus-
sion, researchers will subsequently gain the tools
necessary to improve their nation's domestic handling of
QOL assessment.
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